vs
CRYO CELL INTERNATIONAL INC（CCEL）与费森尤斯医疗（FMS）财务数据对比。点击上方公司名可切换其他公司
费森尤斯医疗的季度营收约是CRYO CELL INTERNATIONAL INC的698.1倍（$5.5B vs $7.8M）。费森尤斯医疗净利率更高（7.9% vs -48.7%，领先56.6%）。费森尤斯医疗同比增速更快（-0.3% vs -2.3%）
Cryo-Cell国际是一家脐带血库企业，由丹·理查德于1989年创立，是全球首家分离并储存干细胞的民营脐带血库，总部位于佛罗里达州奥兹马尔，地处坦帕市郊。
费森尤斯医疗是德国知名医疗保健企业，核心业务为肾脏透析服务，在全球运营4171家门诊透析中心，服务约34.54万名患者。公司主要为终末期肾病患者提供治疗服务，该类患者需终身每周接受3次透析治疗以维持生命。
CCEL vs FMS — 直观对比
营收规模更大
FMS
是对方的698.1倍
$7.8M
营收增速更快
FMS
高出2.0%
-2.3%
净利率更高
FMS
高出56.6%
-48.7%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $7.8M | $5.5B |
| 净利润 | $-3.8M | $434.2M |
| 毛利率 | 77.9% | 27.4% |
| 营业利润率 | -50.6% | 11.7% |
| 净利率 | -48.7% | 7.9% |
| 营收同比 | -2.3% | -0.3% |
| 净利润同比 | -105.1% | 240.4% |
| 每股收益（稀释后） | $-0.46 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CCELFMS
| Q4 25 | $7.8M | $5.5B | ||
| Q3 25 | $7.8M | — | ||
| Q2 25 | $7.9M | — | ||
| Q1 25 | $8.0M | — | ||
| Q4 24 | $8.0M | $5.5B | ||
| Q3 24 | $8.1M | — | ||
| Q2 24 | $8.0M | — | ||
| Q1 24 | $7.9M | — |
净利润CCELFMS
| Q4 25 | $-3.8M | $434.2M | ||
| Q3 25 | $749.4K | — | ||
| Q2 25 | $355.8K | — | ||
| Q1 25 | $282.9K | — | ||
| Q4 24 | $-1.9M | $127.6M | ||
| Q3 24 | $1.1M | — | ||
| Q2 24 | $655.8K | — | ||
| Q1 24 | $556.2K | — |
毛利率CCELFMS
| Q4 25 | 77.9% | 27.4% | ||
| Q3 25 | 77.0% | — | ||
| Q2 25 | 76.6% | — | ||
| Q1 25 | 75.1% | — | ||
| Q4 24 | 78.4% | 25.0% | ||
| Q3 24 | 73.6% | — | ||
| Q2 24 | 74.8% | — | ||
| Q1 24 | 73.7% | — |
营业利润率CCELFMS
| Q4 25 | -50.6% | 11.7% | ||
| Q3 25 | 24.3% | — | ||
| Q2 25 | 18.8% | — | ||
| Q1 25 | 13.3% | — | ||
| Q4 24 | -1.5% | 5.1% | ||
| Q3 24 | 17.2% | — | ||
| Q2 24 | 17.3% | — | ||
| Q1 24 | 10.5% | — |
净利率CCELFMS
| Q4 25 | -48.7% | 7.9% | ||
| Q3 25 | 9.6% | — | ||
| Q2 25 | 4.5% | — | ||
| Q1 25 | 3.5% | — | ||
| Q4 24 | -23.2% | 2.3% | ||
| Q3 24 | 13.0% | — | ||
| Q2 24 | 8.2% | — | ||
| Q1 24 | 7.1% | — |
每股收益（稀释后）CCELFMS
| Q4 25 | $-0.46 | — | ||
| Q3 25 | $0.09 | — | ||
| Q2 25 | $0.04 | — | ||
| Q1 25 | $0.03 | — | ||
| Q4 24 | $-0.23 | — | ||
| Q3 24 | $0.13 | — | ||
| Q2 24 | $0.08 | — | ||
| Q1 24 | $0.07 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $3.3M | $1.7B |
| 总债务越低越好 | $8.4M | — |
| 股东权益账面价值 | $-18.6M | $15.4B |
| 总资产 | $61.7M | $33.5B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CCELFMS
| Q4 25 | $3.3M | $1.7B | ||
| Q3 25 | $3.2M | — | ||
| Q2 25 | $4.4M | — | ||
| Q1 25 | $3.5M | — | ||
| Q4 24 | $3.5M | $1.3B | ||
| Q3 24 | $2.1M | — | ||
| Q2 24 | $1.5M | — | ||
| Q1 24 | $979.6K | — |
总债务CCELFMS
| Q4 25 | $8.4M | — | ||
| Q3 25 | $8.4M | — | ||
| Q2 25 | $8.4M | — | ||
| Q1 25 | $8.5M | — | ||
| Q4 24 | $8.5M | — | ||
| Q3 24 | $8.5M | — | ||
| Q2 24 | $8.5M | — | ||
| Q1 24 | $8.6M | — |
股东权益CCELFMS
| Q4 25 | $-18.6M | $15.4B | ||
| Q3 25 | $-14.8M | — | ||
| Q2 25 | $-15.6M | — | ||
| Q1 25 | $-14.7M | — | ||
| Q4 24 | $-13.2M | $17.0B | ||
| Q3 24 | $-9.6M | — | ||
| Q2 24 | $-10.7M | — | ||
| Q1 24 | $-10.3M | — |
总资产CCELFMS
| Q4 25 | $61.7M | $33.5B | ||
| Q3 25 | $63.2M | — | ||
| Q2 25 | $64.4M | — | ||
| Q1 25 | $64.4M | — | ||
| Q4 24 | $64.7M | $36.3B | ||
| Q3 24 | $62.9M | — | ||
| Q2 24 | $62.6M | — | ||
| Q1 24 | $61.7M | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $1.3M | $2.9B |
| 自由现金流经营现金流 - 资本支出 | $1.2M | — |
| 自由现金流率自由现金流/营收 | 15.5% | — |
| 资本支出强度资本支出/营收 | 0.9% | — |
| 现金转化率经营现金流/净利润 | — | 6.67× |
| 过去12个月自由现金流最近4个季度 | $5.2M | — |
8季度趋势，按日历期对齐
经营现金流CCELFMS
| Q4 25 | $1.3M | $2.9B | ||
| Q3 25 | $2.5M | — | ||
| Q2 25 | $707.0K | — | ||
| Q1 25 | $954.1K | — | ||
| Q4 24 | $2.2M | $2.6B | ||
| Q3 24 | $2.4M | — | ||
| Q2 24 | $1.8M | — | ||
| Q1 24 | $-356.9K | — |
自由现金流CCELFMS
| Q4 25 | $1.2M | — | ||
| Q3 25 | $2.5M | — | ||
| Q2 25 | $644.6K | — | ||
| Q1 25 | $892.0K | — | ||
| Q4 24 | $2.1M | — | ||
| Q3 24 | $2.3M | — | ||
| Q2 24 | $21.5K | — | ||
| Q1 24 | $-814.6K | — |
自由现金流率CCELFMS
| Q4 25 | 15.5% | — | ||
| Q3 25 | 31.9% | — | ||
| Q2 25 | 8.1% | — | ||
| Q1 25 | 11.2% | — | ||
| Q4 24 | 26.8% | — | ||
| Q3 24 | 27.9% | — | ||
| Q2 24 | 0.3% | — | ||
| Q1 24 | -10.4% | — |
资本支出强度CCELFMS
| Q4 25 | 0.9% | — | ||
| Q3 25 | 0.5% | — | ||
| Q2 25 | 0.8% | — | ||
| Q1 25 | 0.8% | — | ||
| Q4 24 | 0.1% | — | ||
| Q3 24 | 2.3% | — | ||
| Q2 24 | 21.8% | — | ||
| Q1 24 | 5.8% | — |
现金转化率CCELFMS
| Q4 25 | — | 6.67× | ||
| Q3 25 | 3.38× | — | ||
| Q2 25 | 1.99× | — | ||
| Q1 25 | 3.37× | — | ||
| Q4 24 | — | 20.20× | ||
| Q3 24 | 2.32× | — | ||
| Q2 24 | 2.70× | — | ||
| Q1 24 | -0.64× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
